Jagsonpal Pharmaceuticals Announces FY Results and Recommends Rs. 4 Dividend Per Share
Jagsonpal Pharmaceuticals Limited announced its audited (standalone) financial results for the quarter and year ended March 31, 2026. Following the Board of Directors meeting on April 27, 2026, the company also recommended a final dividend of Rs. 4/- per equity share for the fiscal year 2025-26.The company confirmed that the results presented for the year ended March 31, 2026, have been audited by the statutory auditors, Walker Chandiok & Co LLP. The auditors provided an opinion that the financial results give a true and fair view of the net profit after tax and other comprehensive income in conformity with applicable Indian Accounting Standards (Ind AS).
Financial Performance Summary
Jagsonpal Pharmaceuticals reported significant operational figures for the fiscal year 2025-26. The comprehensive financial data for the year ended March 31, 2026, compared to the previous year (March 31, 2025), shows the following key figures (in Million Rs):| Particulars | As at 31 March 2026 | As at 31 March 2025 |
|---|---|---|
| Total non-current assets | 1,735.88 | 1,170.66 |
| Total current assets | 1,430.89 | 1,611.94 |
| Total equity | 2,761.72 | 2,399.50 |
| Total non-current liabilities | 122.07 | 124.06 |
| Total current liabilities | 282.98 | 259.04 |
Profit and Loss Highlights (in Rs. Million):
| Metric | Q End 31 March 2026 (Audited) | Year Ended 31 March 2026 (Audited) |
|---|---|---|
| Revenue from operations | 642.03 | 2,872.25 |
| Total Income (Revenue + Other Income) | 673.71 | 2,769.06 |
| Total Expenses | 56.15 | 2,396.23 |
| Net profit for the year | 87.62 | 430.82 |
| Total comprehensive income | 88.72 | 434.46 |
| Basic Earnings per Share (Rs.) | 1.25 | 6.40 |
Dividend and Corporate Actions
The Board of Directors recommended a dividend of Rs. 4/- per equity share, representing 200% of the face value of Rs. 2.Furthermore, the Board of Directors had previously approved a buy-back of up to 1,600,000 fully paid-up equity shares of the company. This buyback is set at a price of Rs. 2.50 per equity share, for an aggregate consideration not exceeding Rs. 400 million.
Cash Flow and Operational Insights
Analyzing the company's financial health through cash flows reveals strong cash generation over the past year.The audited Cash Flow Statement data highlights the following (in Rs. Million):
| Description | Year Ended 31 March 2026 | Year Ended 31 March 2025 |
|---|---|---|
| Net cash from operating activities | 468.12 | 551.13 |
| Net cash used in investing activities | (356.49) | (451.47) |
| Net cash used in financing activities | (121.49) | (116.98) |
| Cash and cash equivalents at the end of the year | 100.42 | 110.28 |
Capital Structure:
The Statement of Financial Results also provides a view of the company's capital base:
| Description | 31 March 2026 | 31 March 2025 |
|---|---|---|
| Equity share capital | 133.93 | 132.80 |
| Other equity | 2,627.79 | 2,266.70 |
| Total equity | 2,761.72 | 2,399.50 |
The company is primarily engaged in manufacturing and trading of pharmaceutical products, considering this activity as a single reportable business segment.
***
Note: All financial figures are presented in Million Rupees unless otherwise stated.
JAGSNPHARM Stock Price Movement
Today, Jagsonpal Pharmaceuticals Limited shares edged higher to close at ₹203.67, marking a gain of 2.23% for the day. The equity saw robust trading activity of 148,205 shares, finishing its session well above its intraday low of ₹202.66.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: